Introduction
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease entity originating from germinal center (GC) or post-GC B cells such as plasmablasts. [1] [2] [3] [4] The majority of DLBCL can be classified according to cell-of-origin gene expression profile, as either germinal center (GC-DLBCL) or activated B-cell (ABC-DLBCL) subtype. [5] [6] [7] [8] [9] While addition of rituximab to CHOP chemotherapy has improved DLBCL patients' survival significantly, 10 new therapies are needed for non-responding or relapsed patients (reviewed in 11 ).
Novel molecularly-targeted therapies are being sought particularly for the poorer prognosis ABC-DLBCL subtype following identification of key biological pathways contributing to disease pathogenesis such as NF-κB pathway mutations and activation, [12] [13] [14] [15] B-cell receptor (BCR) signaling, 16 MALT1 inhibition, 17 and BLIMP1 mutations. 18 Maintenance of BCR signaling and prevention of plasma cell maturation to disrupt normal maturation/differentiation pathways is a common paradigm.
High FOXP1 expression correlates with the ABC-DLBCL subtype 4 and poor clinical outcome in both pre-and post-rituximab eras. [19] [20] [21] [22] FOXP1 amplification and trisomy have been described in ABC-DLBCL, 23 and translocations involving the immunoglobulin heavy chain (IGH) locus 24 drive expression of a long ~75kDa FOXP1 protein (FOXP1 L ) that may contribute to GC-DLBCL tumor growth by potentiating Wnt/β-catenin signaling. 25 Also, we have described abundant expression of short ~65kDa activation-induced FOXP1 proteins (FOXP1 S ) in ABC-DLBCL. 26 Oncogenic activity of N-terminally truncated FOXP1 has been proposed following its truncation by an oncogenic virus 27 and non-IGH translocations targeting the FOXP1 coding region in lymphoma.
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Studies manipulating Foxp1 expression have established biological roles in early B-cell development 30, 31 and in mature B-cells. 32 Direct FOXP1 target genes, including PAX5, PRDM1, and POU2F1, support a functional role in the GC reaction. 32 Recent studies have provided insight into FOXP1 function in DLBCL cells, indicating contributions to proliferation, 33 inhibition of apoptosis to compliment NF-κB-dependent regulation of proliferation, 34 and Wnt signaling.
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However, further understanding of FOXP1 isoform expression and functionality is required to pursue emerging evidence indicating that FOXP1 L and FOXP1 S proteins have distinct functions.
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Here we demonstrate that FOXP1 S proteins in DLBCL are encoded by transcripts with alternate 5 non-coding exons, not internal exon skipping. 26 We identify a novel alternate long FOXP1
protein (designated FOXP1 AL ) and a GC B-cell population lacking the FOXP1 L N-terminus.
Isoform-biased FOXP1 depletion altering FOXP1 L :FOXP1 S stoichiometry regulates expression of CD19 in DLBCL cell lines, providing further evidence for isoforms having distinct functional roles in B-cell biology.
Methods
Cell culture
DLBCL and myeloma lines were sourced and cultured as described previously. 26 
COS-1, 293T
and NIH-3T3 (ATCC) were cultured in DMEM containing 10% fetal bovine serum (Life Technologies, Paisley, UK), and murine B-cell lines 5TGM1-GFP (a gift of Claire Edwards, Oxford) and A20 (ATCC) in RPMI containing 10% serum, 100µM non-essential amino acids, 1mM sodium pyruvate, 50µM 2-mercaptoethanol.
Primary human samples
DLBCL patient samples were collected with informed consent obtained in accordance with the Declaration of Helsinki, and the study was performed under local ethics committee approval from the Leeds West Regional Ethics Committee, Leeds, United Kingdom. RNA was isolated from DLBCL samples obtained prior to therapy as described. 26 Primary B cells from blood buffy-coat preparations (National Blood Service, Bristol, United Kingdom) were activated with 50µg/ml antiIgM or 1:20,000 SAC plus 5ng/ml recombinant human IL-2 (Sigma, St Louis USA). Reactive tonsils were obtained with informed consent from John Radcliffe Hospital, Oxford and studies conducted under ethical approval from NRES Committee South Central -Oxford B (C02.162).
Gene expression analyses
Random-primed cDNA was prepared from total RNA according to manufacturer's protocols (Life Technologies), and real-time PCR analyses performed by Chromo4 (BioRad, Herts UK) using
Express qPCR supermix or SYBR GreenER supermix (Life Technologies), and primers/probes as detailed in Supplemental Table 1 . Standard RT-PCR to discriminate FOXP1-6b(L/S) transcripts used forward Ex6b(L)#1, Ex6b(L)#2, Ex6b(S), or control forward primers Ex6 or Ex8, all paired with reverse primer Ex10 (Supplemental Table 1 ). RNAseq analysis was performed on NCBI Gene Expression Omnibus (GEO) lymphoma dataset GSE50721.
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Immunoblot and immunoprecipitation
Whole cell extracts were prepared in RIPA, or nuclear and cytoplasmic extracts by commercial reagent (Affymetrix, High Wycombe UK). Immunoprecipitations from 50µg nuclear lysate were performed in IP buffer (1% Triton, 150mM NaCl, 10mM Tris, 1mM EDTA) and complexes purified using μMACS Protein G microbeads (Miltenyi Biotec, Surrey UK). Primary antibody details are in Supplemental Table 1 .
Mass spectrometry
JC12 immunoprecipitates were subjected to parallel SDS-PAGE analyses for immunoblotting and silver staining. Stained bands corresponding to ~65kDa and ~75kDa FOXP1 proteins were excised, subjected to reduction, alkylation and trypsin digestion, and resulting peptides identified by Mass Spectrometry as previously 36 with formic acid modified to 0.1% in the gradient.
Immunohistochemistry
After formalin fixation, paraffin embedding and sectioning, slides were dewaxed and antigen retrieved by microwaving in 50mM Tris, 2mM EDTA pH9.0. Immunostaining with primary antibodies (Supplemental Table 1 ) was followed by secondary antibody and detection (EnvisionDako, Ely UK).
Flow cytometry
Cells were labeled in PBS containing 0.5% bovine serum albumin, 2mM EDTA with primary antibodies (Supplemental Table 1 ) and/or isotype controls, and/or secondary antibody (streptavidin APC, eBioscience) and data obtained by FACSCalibur (Becton Dickinson, San Jose USA).
Transfection
For over-expression, cells were harvested 48hr after transfection with pcDNA4-HisMax expression vectors encoding human FOXP1-4 proteins using Lipofectamine (Life Technologies).
For knockdown, cells were electroporated in the presence of 1µM Stealth siRNA duplexes (Life Technologies, Supplemental Table 1 ) using Amaxa Nucleofector (Lonza, Slough UK) generally using Solution L, program X-001.
Results
Short FOXP1 proteins (FOXP1 S ) in ABC-DLBCL lack the N-terminus
We used mass spectrometry to characterize FOXP1 S and FOXP1 L proteins immunoprecipitated from GC-and ABC-DLBCL cell lines ( Figure 1 A- Figure 1 A-D). Thus this reagent was used to study only nuclear expression in cell lines and tissues with known FOXP2 status. In DLBCL nuclear extracts this Nterminal antibody recognized only FOXP1 L , while our anti-C-terminal JC12 antibody detected both FOXP1 S and FOXP1 L proteins ( Figure 1C ). Thus FOXP1 S proteins in multiple ABC-DLBCL cell lines lack the N-terminal epitopes encoded by Ex7. 26 The N-terminal antibody was ineffective at routinely distinguishing ABC-versus GCB-DLBCL cell lines by immunohistochemistry (Supplemental Figure 2A) , reflecting FOXP1 L co-expression, non-specific cytoplasmic staining, and FOXP2 expression in RIVA. Interestingly, immuno-precipitation of FOXP1 L using the Nterminal antibody co-immunoprecipitated FOXP1 S , providing evidence for a physical FOXP1 L -FOXP1 S interaction in ABC-DLBCL (Supplemental Figure 1E) .
A rare subset of germinal center B-cells lack the FOXP1 L N-terminus
The ABC-DLBCL cell-of-origin is proposed to be a plasmablastic B-cell poised to exit the GC.
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Tonsillar B-cell follicles (FOXP2-negative) consistently exhibited comparable intensity and pattern of mantle zone staining when immunolabeled with N-and C-terminal FOXP1 antibodies ( Figure 1D ). However, rare GCs in some tonsils contained a small subpopulation of strongly Figure 3C ).
Malignant mature murine B cells express Foxp1 S protein and N-terminally truncated Foxp1
transcripts partially conserved with mature human B-cells.
Cross-species conservation supports biological significance, and a murine Foxp1 S isoform termed Foxp1D (initiating exon originally designated mEx2b, 37 revised to mEx5b 38 ) has been described.
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Multiple transcripts with alternate non-coding 5 exons encoding murine Foxp1 S protein in a murine B-cell lymphoma model, A20, that expresses both Foxp1 L and Foxp1 S proteins were investigated (Supplemental Figure 4A) . Comparisons of the murine Foxp1 genomic sequence with alternate 5 exons in human FOXP1 transcripts identified potential murine exons with homology to human Ex6b (mEx4b), Ex7b (mEx5b) and Ex7c (mEx5c) (Supplemental Figure 4 B-C).
However, the revised mEx2b alternate 5 exon (predicted to encode Foxp1 L or Foxp1A 37 ) had only low similarity to human Ex4a sequences. Importantly, expression of Foxp1 S -coding murine transcripts containing alternate 5 exon mEx4b or mEx5b was detectable in the malignant mature B-cell lines A20 and 5TGM1 and associated with reduced expression of Foxp1 L Ex2-4 transcripts (Supplemental Figure 4D ). Despite the significance of Ex7c in human DLBCL, transcripts containing its potential murine equivalent (mEx5c) could not be reliably detected. In summary, multiple transcripts with alternate 5 exons contribute to FOXP1 S protein expression in both murine and human lymphoma. 
Discussion
Characterization of FOXP1 isoform complexity in both human and murine lymphoma cells is important to understand their roles in lymphoma biology and clinical relevance.
We have proven our original hypothesis 26 that FOXP1 S proteins in ABC-DLBCL lack the Nterminus using both mass spectrometry and a commercially available polyclonal N-terminal
antibody. An improved N-terminal antibody, lacking the non-FOXP1 cytoplasmic cross-reactivity and nuclear FOXP2 cross-reactivity seen with the current antibody, might routinely identify strongly JC12 + (FOXP1 C-terminal epitope) DLBCL that lack the N-terminus. Despite its limitations the current polyclonal antibody may be of interest within the research community e.g. isoforms in relation to developmental blocks in DLBCL may also lead to the identification of novel therapeutic differentiation strategies for this disease.
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